Introduction {#s02}
============

Preceded by valiant efforts in Berlin, Strasbourg, Baltimore, and Bucharest, insulin was discovered in Toronto in 1921 by Fredrick Banting and Charles Best, with auspicious advice and support from John Macleod, and its purification was made possible by James Collip. The story of its discovery is legendary and was awarded the Nobel Prize in Physiology or Medicine in 1923 ([@bib101]), but the journey of this hormone in the body has not been "romanced" as much. Insulin is the paramount anabolic hormone (promoting dietary carbon source deposition), and its synthesis, quality control, delivery, and action are exquisitely regulated in different organs or "stations" of its bodily journey. These functions are enacted by highly orchestrated intracellular mechanisms, starting with production in the β-cells of the pancreas, on to its partial clearance by the liver hepatocytes, followed by its delivery and action on the vascular endothelium and its functions at level of the brain, muscle fibers, and adipocytes (major action sites), and ending with insulin degradation in the kidney. As such, the journey of insulin in the body is a superb example of integrated cellular physiology.

In this *Beyond the Cell* review, we focus on five stages of the journey of insulin through the body and the captivating cell biology that underlies its connections with each organ. We analyze insulin's biosynthesis in and release from β-cells of the pancreas, its first pass and partial clearance in the liver, its action on the blood vasculature and exit from the capillary beds, its action in the central nervous system in brief, followed by its stimulation of muscle and adipose cell glucose uptake, and its degradation in the kidney to finalize its action ([Fig. 1](#fig1){ref-type="fig"}).

![**Journey of insulin in the body.** Insulin is transcribed and expressed in the β-cells of the pancreas, from whence it is exported through the portal circulation to the liver. During this first pass, over 50% of insulin is cleared by the hepatocytes in the liver. The remaining insulin exits the liver via the hepatic vein, where it follows the venous circulation to the heart. Insulin is distributed to the rest of the body through the arterial circulation. Along the arterial tree, insulin promotes vasodilation. Arterially delivered insulin exerts its metabolic actions in the liver and is further cleared (second pass). Insulin exits the circulation at the level of the microvasculature, reaching muscle and fat cells, where it stimulates GLUT4 translocation and glucose uptake. Remaining circulating insulin is delivered to and finally degraded by the kidney. This review analyzes the cellular processes at each stage of this journey. This figure was created using Servier Medical Art (available at <https://smart.servier.com/>).](JCB_201802095_Fig1){#fig1}

By necessity, many aspects of the metabolic actions of insulin are not reviewed here; rather, we present the most current picture of each phenomenon, highlighting up-to-date concepts and spatial-temporal coordinates. By applying a cell biology lens to the five fundamental stages in insulin's journey in the body, we hope to render an integrated view of insulin "within and beyond the cell." Of major relevance, though not individually discussed here, defects in each station of the hormone's journey in the body have been correlated and often causally related to insulin resistance, hypertension, and type 2 diabetes ([@bib196]; [@bib86]; [@bib150]; [@bib23]; [@bib47]; [@bib169]; [@bib80]; also see other important highlights in the text box).

Selected examples of mechanistic defects in the five stages of the journey of insulin, associated with insulin resistance and type 2 diabetes {#s03}
---------------------------------------------------------------------------------------------------------------------------------------------

• Defective insulin exocytosis from diabetic β-cells ([@bib58]; [@bib68]) and impaired pulsatile secretion of insulin in diabetic individuals ([@bib118]; [@bib87]; [@bib116])

• Reduced hepatic insulin clearance ([@bib97]) and CEACAM1 expression ([@bib120]) in obesity

• Impaired vasoactive effects of insulin during insulin resistance, including capillary recruitment ([@bib48]; [@bib39]; [@bib105]); reduced insulin delivery to muscle in obesity and diabetes ([@bib26])

• Diminished GLUT4 translocation to the muscle membrane in diabetic rodents and humans ([@bib107]; [@bib224]; [@bib72]; [@bib86]; [@bib44]) and lowered expression of Rac1 ([@bib191]) as well as a number of proteins of the GLUT4 vesicle fusion machinery ([@bib7]); the underlying defects include alterations in the maintenance of the storage compartment ([@bib61]; [@bib168]) and in the insulin-derived signals that trigger GLUT4 vesicle release from storage and interaction with the plasma membrane

• Compromised glomerular function in obesity ([@bib99]) that may alter insulin bioavailability; sodium retention and down-regulation of the natriuretic peptide system in insulin resistance ([@bib182]) that may herald hypertension

Biosynthesis and export of insulin in pancreatic β-cells {#s04}
========================================================

Insulin synthesis, processing, and packaging in pancreatic β-cells {#s05}
------------------------------------------------------------------

Humans have a single insulin gene, *INS* (rodents have two, *ins1* and *ins2*), located on chromosome 11, the transcription of which is controlled largely by upstream enhancer elements that bind key transcription factors that include IDX1 (PDX1), MafA, and NeuroD1 along with numerous coregulators ([@bib6]). In the insulin-producing pancreatic β-cells, these are required for insulin gene expression and contribute to the regulation of *INS* transcription in response to glucose and autocrine insulin signaling ([@bib4]). Given the role of these enhancer elements, transcription factors, and their coregulators in controlling the expression of insulin and many additional components of the β-cell secretory pathway, such as glucose transporter 2 (GLUT2) and the insulin processing enzyme PC1/3, they are key defining contributors to the establishment and maintenance of β-cell identity ([@bib69]).

Insulin is translated initially as a preproinsulin ([Fig. 2 A](#fig2){ref-type="fig"}), which is then processed to proinsulin in the RER upon cleavage of its signal sequence by a signal peptidase. In the RER, proinsulin is folded and stabilized in its 3D proinsulin configuration, linking the semihelical A domain and helical B domain via the formation of three disulfide bonds. After transit to the Golgi apparatus, the properly folded proinsulin is sorted into still-immature secretory granules where it is processed via the prohormone convertases PC1/3 and PC2, which cleave the C-peptide. Subsequently, carboxypeptidase E removes C-terminal basic amino acids from the resulting peptide chains, yielding mature insulin consisting of A- and B-peptide chains linked by disulfide bonds ([@bib90]).

![**Insulin biosynthesis and secretion. (A)** Insulin maturation along the granule secretory pathway. Preproinsulin mRNA is transcribed from the *INS* gene and translated to preproinsulin peptide. As this transits through the RER and TGN, the prepropeptide is processed to its mature form and ultimately stored as hexameric insulin/Zn^2+^ crystals within mature secretory granules. **(B)** Glucose sensing and metabolic signals leading to insulin granule secretion. The release of insulin via exocytosis of secretory granules from pancreatic β-cells is controlled by a series of metabolic and electrical signals arising as a result of glucose entry through GLUTs, phosphorylation by GK, and entry into the TCA cycle. The closure of ATP-dependent K^+^ (K~ATP~) channels triggers electrical events that culminate in Ca^2+^ entry through voltage-dependent Ca^2+^ channels (VDCCs), which triggers exocytosis mediated by SNARE complex proteins. The overall secretory response is modulated by numerous receptors, channels, intracellular Ca^2+^ stores, metabolic signals, and cytoskeletal elements. **(C)** Islet communication for coordinated pulsatile insulin secretion. Within an islet, β-cells communicate with each other and with glucagon-producing α-cells and somatostatin (SST)--producing δ-cells to coordinate their activity. Many putative intraislet messengers have been implicated, including ATP, Zn^2+^, γ-aminobutyric acid (GABA), glucagon-like peptide-1 (GLP-1), acetylcholine (ACh), and others. These, along with electrical coupling via gap junctions, are likely important for the physiological coordination of pulsatile insulin secretion.](JCB_201802095_Fig2){#fig2}

Transit of immature secretory granules through the TGN, and their subsequent budding and maturation, is controlled by a host of regulatory proteins, including newly identified vesicle-sorting by proteins such as SORCS1 ([@bib104]) and HID-1 ([@bib52]). Insulin biosynthesis in this manner is generally rapid (less than ∼2 h) and efficient, with only 1--2% of the protein remaining as proinsulin within mature secretory granules where insulin couples with Zn^2+^ and exists as a hexameric crystal with the cation. Transport of the insulin hexamer into the secretory granules is thought to be mediated by ZnT8 or related zinc transporters ([@bib125]).

Insulin granule pools and their intracellular traffic {#s06}
-----------------------------------------------------

Most insulin granules (perhaps 75--95% of an estimated 10,000) are stored within the β-cell cytoplasm at some distance away from the cell membrane ([@bib163]). The remainder move to the cell periphery along microtubule networks in an AMPK- and kinesin1-dependent manner ([@bib137]). To reach the plasma membrane, however, granules must cross a cortical actin network that acts as a physical barrier to insulin secretion ([@bib127]). Actin reorganization is therefore an important component of the early journey of insulin before it can exit the β-cell. The process is coordinated by the action of several small G-proteins and their activating nucleotide exchange factors. This includes the glucose- and Cdc42-dependent activation of Rac1, which, when released from an inhibitory RhoGDI and in its GTP-bound form, promotes cortical actin remodeling, perhaps via an interaction with gelsolin ([@bib98]). Finally, secretory granules must dock at the plasma membrane and be chemically "primed" in response to an intracellular Ca^2+^ signal ([Fig. 2 B](#fig2){ref-type="fig"}).

The coordinated interaction of exocytic machinery proteins in association with Ca^2+^ channels ([@bib68]) ensures assembly of an insulin granule--exocytic site complex that is "ready to go" when needed. These events likely underlie the well-described biphasic nature of glucose-evoked insulin secretion seen in vitro: a rapid first phase resulting from fusion and secretion by already "docked and primed" secretory granules that in human lasts up to 10 min, and a subsequent second-phase secretion that is associated with actin reorganization thought to allow granule recruitment to the plasma membrane ([@bib208]).

The orderly arrival, priming, docking, and fusion of granules is exquisitely coordinated in response to physiological inputs initiated by glucose and decoded by the β-cell, as described next.

Sensing glucose: Metabolism-controlled electrical signals and Ca^2+^ activity {#s07}
-----------------------------------------------------------------------------

Glucose is the paramount metabolic signal eliciting insulin secretion, and a consensus model reveals a relay of chemical to electrical on to mechanical signals ([Fig. 2 B](#fig2){ref-type="fig"}). In brief, glucose enters through the cell membrane glucose transporters GLUT2 in rodents and GLUT1 in humans ([@bib136]). Glucose is rapidly phosphorylated by glucokinase (GK) to generate glucose-6-phosphate, which, through glycolysis, feeds the mitochondrial TCA cycle. GK, an isoform of hexokinase, effectively generates downstream signaling metabolites (i.e., ATP and pyruvate) within a range of glucose concentrations that matches the normal physiological range for plasma glucose homeostasis ([@bib139]). For this reason, the tandem GLUT1/2 and GK is often referred to as a glucose-sensor controlling blood sugar levels. Mutations that alter the glucose-dependent activity of GK effectively adjust the set point for whole-body glucose homeostasis ([@bib73]).

Pyruvate generated from glycolysis enters the mitochondria via mitochondrial pyruvate carriers ([@bib153]), where the TCA cycle--dependent generation of NADH promotes the export of H^+^ from the mitochondrial matrix by the electron transport chain, and then generation of ATP from ADP by ATP synthase, which itself appears dependent on mitochondrial Ca^2+^ uptake ([@bib198]). Subsequent increases in the cytosolic ATP/ADP ratio control cell membrane potential by inhibiting ATP-sensitive K^+^ (K~ATP~) channels, eliciting a membrane depolarization that is modulated by a number of additional ion channels ([Fig. 2 B](#fig2){ref-type="fig"}). This represents the conversion of chemical to electrical signaling. When the membrane potential depolarizes sufficiently (approximately −50 mV), the activation of voltage-dependent Na^+^ and Ca^2+^ channels cause repetitive action potential spiking and a rise in intracellular Ca^2+^ ([@bib164]). Ca^2+^ thus becomes the "currency\" that triggers granule fusion with the plasma membrane. The increase in cytosolic Ca^2+^ is rapidly reversed by very active Ca^2+^ pumps such as the ER sarco-ER Ca^2+^-ATPase (SERCA), and the use of ATP in the entire process might feed back to activate AMPK and promote insulin granule migration toward the cell periphery. Additional important feedback between Ca^2+^ and intracellular signals should be noted. For example, feedback from oscillatory Ca^2+^ signals controls mitochondrial ATP generation ([@bib197]), and recent work shows that Ca^2+^ oscillations and the ER protein TMEM24 interact at ER--plasma membrane contact sites to maintain phosphatidylinositol levels required for β-cell signaling and insulin secretion ([@bib124]).

Importantly, cells across the entire islet, and islets across the entire pancreas, coordinate their Ca^2+^ signals to effect insulin secretion that occurs as rhythmic oscillations. Although pancreatic β-cells are electrically excitable in response to glucose, they do not work in isolation: they talk to each other. The electrical and Ca^2+^-responses of β-cells within an islet are synchronized ([@bib220]) and perhaps even coordinated by pacemaker (or "hub") β-cells within the islet ([@bib96]). Gap junction coupling between β-cells via connexin36 plays a critical role, the loss of which results in dysregulation of insulin secretion ([@bib161]). Paracrine and autocrine signaling among β-cells also likely contributes to the coordination and amplification of electrical and Ca^2+^ responses. Transmitter molecules secreted by β-cells themselves, such as ATP ([@bib79]), among others, likely modulate the excitatory activity of nearby β-cells, thus controlling islet Ca^2+^ and insulin secretory responses ([Fig. 2 C](#fig2){ref-type="fig"}).

Thus, communication between cells within an islet likely contributes to the well-described phenomenon of insulin secretory oscillations, which occur in healthy humans with a periodicity of 5--10 min ([@bib176]). The electrical activity and intracellular Ca^2+^ responses in β-cells within rodent and human islets also oscillates, ranging from tens of seconds to ∼5 min ([@bib46]; [@bib84]). Further information is provided in [Fig. 2 B](#fig2){ref-type="fig"} and in recent modeling that integrates metabolic, electrical, and Ca^2+^ feedback to produce these oscillations ([@bib17]). Importantly, this translates into oscillations of insulin secretion from isolated islets, again with a periodicity of 1--5 min ([@bib16]).

On top of this, the translation of this single-islet oscillatory activity into a pulsatile release of insulin from the whole pancreas in vivo requires coordination among many individual islets (perhaps a million within a human pancreas). It is not entirely clear how islets within a pancreas communicate in order to synchronize their oscillations. Strong recent evidence suggests a key role for an intrapancreatic neural network, which could coordinate activity among disparate islet populations. This "neuroinsular network" was most recently demonstrated by elegant 3D imaging techniques in rodent ([@bib195]) and human ([@bib194]) pancreata.

The glucose-dependent increase in cytosolic ATP/ADP, closure of K~ATP~ channels, and initiation of electrical activity to increase Ca^2+^ and trigger insulin exocytosis has been a useful consensus model for regulated insulin secretion for more than 35 yr. However, this model oversimplifies the physiological regulation of insulin secretion. It has been long recognized that additional signals from gut-derived hormones, autonomic inputs, glucose metabolism itself, and paracrine signals from neighboring α- and δ-cells impinge on this model to exert important control on insulin secretion ([Fig. 2 C](#fig2){ref-type="fig"}). Many of these signals "amplify" the secretory response, either by modulating the electrical/Ca^2+^ responses of β-cells or by controlling the efficacy of Ca^2+^-triggered insulin exocytosis. For example, the gut-derived hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide together mediate the "incretin" effect whereby nutrient sensing in the gut signals to islets to augment the insulin secretory response to glucose ([@bib51]). These hormones act on classical G-protein--coupled receptors via Gα~s~-activation of adenylate cyclase to increase cAMP, which causes PKA-dependent phosphorylation of the exocytic machinery and PKA-independent effects mediated by Epac2A to promote the release of Ca^2+^ from intracellular stores ([@bib109]). Recently, Epac2A was also shown to regulate insulin granule priming ([@bib3]).

Although a glucose-dependent rise in the intracellular ATP/ADP ratio is critical for eliciting β-cell electrical and Ca^2+^ responses, other mitochondria-derived signals are also important determinants of the secretory response to that Ca^2+^ rise. Hence, glucose not only controls the Ca^2+^ signals that trigger insulin secretion but also generates signals that improve the efficacy of Ca^2+^ on the secretory process, likely by acting on the Ca^2+^ sensitivity of diverse components in the pathway ([@bib83]). This is likely behind the glucose-dependent improvement in insulin granule docking-priming, which is also promoted by additional metabolism-derived signals such as glutamate, the fatty acid metabolite monoacylglycerol, and NADPH ([@bib58]). Together, these inputs interact with various elements of the downstream signaling machinery to effectively amplify secretory responses to a Ca^2+^ signal. The metabolic signals controlling electrical activity and exocytic function ultimately determine the timing and magnitude of insulin secretion. This concerted mechanism accounts for the first phase insulin that takes place with 30 min (during a glucose tolerance test in humans). A second phase lasting up to 120 min ensues that may involve new insulin synthesis.

Insulin granule exocytosis {#s08}
--------------------------

Insulin granules in apposition to the plasma membrane dock with the membrane through the coordinated interaction and recruitment of exocytic SNARE proteins that include SNAP-25, VAMP-8, and syntaxins 1A and 3 ([@bib66]). Loss of key SNARE proteins results in impaired insulin secretion ([@bib128]). The formation and fidelity of the SNARE complex mediating granule docking is regulated by a number of proteins such as Munc18 and syntaxin isoforms ([@bib67]; [@bib223]). Assembly of the exocytic site in β-cells includes the association of insulin granules with L-type Ca^2+^ channels ([@bib68]), which ensures efficient delivery of Ca^2+^ to the secretory vesicle Ca^2+^ sensor, synaptotagmin VII. Collectively, these mechanisms trigger the fusion of the insulin granule bilayer with the plasma membrane, with subsequent release of insulin.

Insulin release occurs directly into the interstitial space of the pancreas, which is surrounded by a fenestrated endothelial vasculature. In this way, released insulin readily finds its way into the portal circulation to be delivered directly to the liver for "first pass."

Insulin clearance by the liver: Its receptor-mediated endocytosis and degradation {#s09}
=================================================================================

Pulsatile delivery of insulin through the portal vein to the liver {#s10}
------------------------------------------------------------------

The liver is the first organ that insulin encounters along its journey. Accordingly, the liver is uniquely exposed to higher concentrations of insulin than other insulin-responsive tissues such as muscle and fat. The portal vein delivers insulin from the pancreas to the liver in discrete pulses that occur every ∼5 min ([@bib181]), where the amplitude of these insulin pulses is 0.5--1 nmol/liter in the fasted state and rises to ∼5 nmol/liter after a meal ([@bib155]; [@bib181]). Pulsatile insulin delivery to the liver is an important physiological signal that regulates both hepatic insulin action ([@bib135]) and insulin clearance ([@bib140]), although the cellular underpinnings of how hepatocytes sense pulsatility are unknown.

The liver acts as a gatekeeper that regulates the amount of insulin reaching peripheral tissues through a process called insulin clearance, which was first observed in dogs ([@bib186]). The concentration of insulin arriving to the liver by the portal vein can be up to 10-fold higher than the concentration in the peripheral circulation ([@bib88]), and the maintenance of this portal-systemic gradient is mediated by substantial insulin degradation by the liver. In humans, simultaneous measurements of portal vein and peripheral vein insulin concentrations during constant glucose infusion revealed that upwards of 50% and possibly even 80% of insulin arriving to the liver by the portal vein is degraded during first-pass hepatic clearance ([@bib140]), and ∼25% of the circulating insulin is degraded upon its second pass through the liver, so that the circulating concentration of insulin is one third that in the portal circulation ([@bib186]). This degradation is coupled to pulsatile delivery, such that the liver preferentially clears insulin that arrives in pulses ([@bib140]). Although it seems counterintuitive that so much insulin would be disposed of, degradation appears to be the default mechanism that is however modulated by demand to achieve the insulin concentration required at the periphery. Indeed, adaptive decreases in the rate of hepatic insulin clearance ([@bib2]; [@bib97]) have been observed during insulin resistance and act to compensate for decreased insulin sensitivity ([@bib97]). Moreover, although insulin internalization is not required for many of the metabolic actions of insulin in the liver, the internalized insulin receptor (IR) continues to signal at least within early endosomes ([@bib18]). Endosomal signaling may have a differential impact from that emanating exclusively from the cell surface, akin to the differential location-based signaling of the EGF receptor ([@bib15]).

The portal circulation delivers insulin into the capillaries of the sinusoids, which are not supported by a basement membrane and their endothelial cells contain fenestrations ([@bib212]; [@bib25]), together permitting the exchange of contents between the blood and the surrounding liver cells. The unique structure of the hepatic sinusoids allows insulin to easily diffuse out of the circulation and into the perisinusoidal space, where it comes into contact with hepatocytes ([Fig. 3 A](#fig3){ref-type="fig"}).

![**Insulin clearance in the liver. (A)** Insulin is delivered to the hepatic sinusoid, where it freely accesses the liver hepatocytes through the fenestrated sinusoidal endothelium. **(B)** Proposed mechanism for insulin degradation in hepatocytes. Insulin binds to the IR and forms a complex with CEACAM1. Prior to internalization, extracellular IDE begins to degrade receptor-bound insulin. After internalization, endosomal IDE degrades receptor-bound insulin and, once the endosome acidifies and the complex dissociates, also frees insulin. Any remaining insulin or insulin fragments progress toward lysosomes for their complete proteolytic degradation.](JCB_201802095_Fig3){#fig3}

Hepatocytes are the major site of insulin clearance. Early electron microscopy studies revealed that IRs bind ^125^I-insulin on microvilli (interdigitations) of the hepatocyte membrane ([@bib31]). After binding, ^125^I-insulin--IR complexes move to the base of the microvilli, where they associate with clathrin-coated pits ([@bib154]) and internalize by clathrin-mediated endocytosis ([@bib57]). Although still unknown for hepatocytes, IR autophosphorylation is required for insulin uptake by CHO cells ([@bib32]). Consistent with earlier studies, liver-specific IR knockout mice provided direct evidence that receptor-mediated degradation regulates systemic insulin levels and that impairments in this process lead to severe hyperinsulinemia that, in turn, contributes to whole-body insulin resistance ([@bib142]). Of note, mice lacking in the liver the IR substrates 1 and 2 (IRS1,2; adaptor proteins that can bind to the IR to initiate signal transduction) have less severe hyperinsulinemia ([@bib50]) than mice lacking the IR ([@bib142]; [@bib40]), suggesting that canonical insulin signaling via IRS1,2 may not participate in insulin clearance. However, there is no direct mechanistic proof of this or of the involvement of other classical insulin signals.

After insulin binds to its receptor on the hepatocyte surface, endocytosis of the receptor--ligand complex causes a concomitant loss of surface IR ([@bib74]), which is followed by rapid recycling and reinsertion of intact, unbound IRs in the plasma membrane ([@bib74]). These findings are concordant with the physiological intervals of pulsatile delivery, suggesting that hepatocyte IR internalization and reinsertion into the membrane is adaptively entrained to insulin delivery ([@bib140]). In contrast to IR recycling, the fate of internalized insulin differs, as we will describe.

CEACAM1 and insulin-degrading enzyme (IDE): Hepatic molecules driving insulin clearance {#s11}
---------------------------------------------------------------------------------------

Although hepatocytes are not exclusive in their ability to internalize insulin, they highly express the transmembrane glycoprotein CEACAM1 (carcinoembryonic antigen--related cell adhesion molecule 1), which mediates rapid and effective IR-mediated insulin endocytosis ([@bib145]). Mechanistically, CEACAM1 is phosphorylated by the IR, enhancing the formation of an insulin--IR--CEACAM1 complex ([@bib146]; [Fig. 3 B](#fig3){ref-type="fig"}). It is hypothesized that a so-far-unidentified adaptor protein targets the tripartite complex to the AP2 adaptor complex for clathrin-mediated endocytosis ([@bib145]). Tests in nonhepatic cells, on the other hand, show that the IR target protein SHC binds dynamin (a GTPase required for the scission of endocytic vesicles), and this complex contributes to IR internalization ([@bib12]). It is tempting to hypothesize that, in hepatocytes, SHC might be the protein linking the IR to CEACAM1 and thus brings the complex to dynamin-rich regions prone for endocytosis. Consistent with the crucial role of CEACAM1 in hepatic insulin clearance, impairments in insulin-stimulated hepatic CEACAM1 phosphorylation or whole-body depletion of hepatic CEACAM1 cause severe hyperinsulinemia and, consequently, insulin resistance and hyperglycemia ([@bib157]; [@bib167]). Notably, hepatocytes from these mice have impaired insulin-dependent IR endocytosis, which can be rescued by liver-specific reexpression of CEACAM1 ([@bib157]; [@bib167]). Hence, the level of CEACAM1 at the plasma membrane and its phosphorylation may impart physiological fine-tuning regulation to the process of insulin clearance.

The majority of insulin that binds to hepatic IRs is degraded ([@bib53]). The degradation process begins on the membrane immediately after insulin binding, where some insulin is reported to be partially degraded by extracellular IDE before internalization ([@bib218]). After internalization, additional IDE is thought to be targeted to endosomal membranes through its interaction with phosphatidylinositol phosphates ([@bib180]), where it begins to degrade receptor-bound insulin in endosomes ([@bib219]) before acidification occurs ([@bib82]). As endosomes acidify, any remaining insulin or partially degraded insulin that escaped complete degradation by IDE dissociates from the IR ([@bib144]; [Fig. 3 B](#fig3){ref-type="fig"}). Ultimately, these degradation products and any remaining intact insulin are delivered to lysosomes for complete proteolysis ([@bib53]), although lysosomal degradation of insulin is thought to play a minor role in insulin clearance ([@bib54]).

Although the in vitro data strongly indicate that IDE is essential for hepatocyte insulin degradation, the role of IDE in hepatic insulin clearance in vivo is controversial, as some studies report that loss of IDE results in hyperinsulinemia ([@bib56]; [@bib1]), whereas others observed no changes in systemic circulating insulin in the absence of the enzyme ([@bib185]).

Insulin that is not degraded in the liver exits through the hepatic vein, reaching the heart, which pumps insulin into the arterial circulation to be delivered to its target tissues (e.g., skeletal muscle, liver, adipose tissue, and the brain). It is important to note that insulin returns to the liver, this time via the hepatic artery, which pours again into the hepatic sinusoid, where the hormone is subject to a second round of insulin degradation (second pass) within hepatocytes.

Beyond first- and second-pass insulin clearance, the hepatocytes are essential metabolic responders to insulin, where one of the major actions of the hormone is to suppress gluconeogenesis and glycogenolysis ([@bib129]). This ensures that a portion of dietary glucose is effectively stored in the liver and is only released to the rest of the body upon cessation of insulin action (between meals) or upon metabolic demand enacted by other "counterregulatory" hormones ([@bib170]). This is a vast area of study that is however not further discussed here.

Insulin interaction with the vasculature {#s12}
========================================

Hemodynamic insulin action on arteries and arterioles {#s13}
-----------------------------------------------------

The peripheral actions of insulin begin inside the vessels of the systemic circulation, where the hormone exerts its hemodynamic effects on endothelial cells to promote blood flow and ensure its delivery to peripheral tissues ([@bib13]). Endothelial cells line each blood vessel and constitute a crucial interface between the circulation and the tissue parenchyma. In large blood vessels such as the aorta and large arteries, insulin acts on the IR of endothelial cells, causing phosphorylation of the major endothelial IR substrate, IRS2. This leads to activation of class I phosphatidylinositol 3-kinase (PI3K), which signals downstream to the serine and threonine kinase Akt/PKB. In turn, Akt activates endothelial NO synthase to catalyze the conversion of [l]{.smallcaps}-arginine to NO ([@bib152]; [@bib221]). NO is a potent vasodilator that rapidly diffuses to the vessels' outer layer of smooth muscle cells, where it activates intracellular guanylate cyclase to increase cyclic guanosine monophosphate production ([@bib5]). Cyclic guanosine monophosphate--dependent reductions in intracellular Ca^2+^ concentration ([@bib33]) prevent phosphorylation of myosin light chain required for cytoskeletal cross-bridge formation and contraction ([@bib122]; [@bib143]), thereby resulting in vessel relaxation ([Fig. 4 A](#fig4){ref-type="fig"}).

![**Insulin interactions with the vasculature. (A)** Endothelial insulin signaling leading to vasodilation in the macrovasculature. The endothelial cell IR engages its major substrate in these cells, IRS2, leading downstream to activation of Akt. Akt phosphorylates endothelial NO synthase (eNOS), which catalyzes the production of NO from [l]{.smallcaps}-arginine. NO freely diffuses to the underlying vascular smooth muscle layer, where it leads to cyclic guanosine monophosphate production to induce vasorelaxation. **(B)** Possible routes for insulin exit across microvascular endothelial cells toward the interstitial space in muscle and fat tissue. Insulin may cross the microvascular capillary endothelium either paracellularly (between adjacent endothelial cells) or transcellularly (through individual endothelial cells). For the transcellular route, both receptor-mediated and fluid-phase mechanisms of transport have been proposed.](JCB_201802095_Fig4){#fig4}

As a consequence of endothelial NO production, insulin stimulates dilation of arteries and arterioles ([@bib184]; [@bib206]). Within minutes, vasodilation of precapillary arterioles irrigates previously collapsed capillaries with blood carrying insulin (capillary recruitment), thereby promoting insulin delivery to the tissue ([@bib206]). With continued insulin circulation (∼30 min), the hormone induces relaxation of larger, upstream resistance vessels to further promote limb blood flow ([@bib11]). Insulin action in target tissues is temporally linked to these vascular effects ([@bib13]); in particular, the full stimulation of skeletal muscle glucose uptake in vivo is contingent on prior NO-mediated vasodilation ([@bib207]; [@bib24]).

Insulin transit across the microvascular endothelium {#s14}
----------------------------------------------------

Once insulin arrives at the capillaries of skeletal muscle and adipose tissue, it must exit the circulation to reach the parenchymal cells (muscle fibers and adipocytes). Unlike the fenestrated capillaries of the liver, the capillary endothelium in skeletal and adipose tissues is continuous, functioning as a stringent barrier between the circulation and the interstitial space. Each capillary is constituted by a single layer of endothelial cells, supported by interendothelial junctions that selectively restrict the passage of contents between the blood and the tissue. Bergman et al. first reported a delay in muscle insulin action relative to the rise in insulin in the circulation ([@bib110]), and several studies have documented that the capillary endothelium is a barrier to insulin delivery to muscle in vivo, maintaining a disequilibrium between circulating and interstitial insulin levels ([@bib94]; [@bib85]).

Insulin may cross the tight capillary endothelia by two potential routes: transcellular (through individual cells) or paracellular (between neighboring endothelial cells; [Fig. 4 B](#fig4){ref-type="fig"}). Although there is evidence that expression of the IR or vascular insulin signaling is required for overall insulin egress from the circulation toward tissues ([@bib115]; [@bib132]; [@bib141]; [@bib112]), opposing studies challenge a receptor-mediated ([@bib204]; [@bib55]; [@bib211]) or saturable process ([@bib183]). To this day, the exact route (intracellular vs. paracellular) and supporting mechanisms remain a matter of debate ([@bib121]). The impasse in discerning this route lies in the limitation to differentiate in vivo between a distinctly local role of the endothelial IR in the cellular transport of insulin across the endothelium from its complementary role in capillary recruitment. Recent studies that have bypassed the hemodynamic concerns have also yielded opposite results. Thus, even with chemically induced vasodilation, a new endothelial cell-specific IR knockout mouse model ([@bib112]) shows defective insulin delivery and action. In contrast, sophisticated imaging of the muscle distribution of somewhat high doses of fluorescent insulin injected into the circulation was best fitted to a model of distribution that does not obey saturation kinetics, suggesting that the IR may not be a major conduit under these conditions ([@bib211]).

Controversy about the mechanism of insulin transit across the microvasculature also arises upon scrutiny in vitro, as cell culture studies have rendered inconsistent results regarding the precise role of the endothelial IR in the uptake of fluorescently conjugated insulin, potentially dependent on their niche origin: microvascular ([@bib8]) or macrovascular ([@bib209]). Moreover, imaging the internalized insulin, needed to establish the hormone's intracellular route, has required the use of supraphysiological doses of insulin to achieve detectable levels ([@bib209]; [@bib8]), confounding the identification of the physiological mechanism. On the other hand, the uptake of physiological levels of ^125^I-insulin into microvascular endothelial cells has uniformly revealed participation of the IR ([@bib95]; [@bib75]; [@bib93]). This includes the transfer of insulin across cells of the blood--brain barrier ([@bib95]; [@bib75]), an important conduit for the now-recognized neuronal actions of the hormone evinced by the neuron-specific IR gene depletion ([@bib28]). How internalized insulin is spared from degradation in endothelial cells, as opposed to its fate in hepatocytes (described in Insulin clearance by the liver: Its receptor-mediated endocytosis and degradation), remains unsolved. Potentially, this may involve routing of insulin into sorting tubules akin to those recently described for transferrin receptor-mediated transcytosis through blood--brain endothelia ([@bib205]).

Central insulin action: Brief focus on the brain {#s15}
================================================

Emerging from the circulation, insulin begins its multifaceted action on central and peripheral tissues. As outlined above, insulin crosses the blood--brain barrier through a receptor-mediated process ([@bib213]). Thought to be insulin unresponsive in the past, the central nervous system is well recognized to be exquisitely responsive to the incoming hormone ([@bib156]). The concentration of insulin in the cerebrospinal fluid is one third that in the circulation, but it nonetheless fluctuates according to the latter and acts on IR on neurons and glial cells. Notable among the evoked central functions is the regulation of appetite and energy expenditure ([@bib60]; [@bib70]). Insulin regulates appetite by reducing expression of neuropeptide Y and Agouti-related peptide (orexigenic) and, conversely, elevating expression of pro-opiomelanocortin (anorexigenic; [@bib178]). Insulin also exerts trophic and developmental actions on neurons and glial cells, and new evidence suggests it modulates cognition, memory, and mood ([@bib123]). Conversely, central defects in insulin action are emerging as a potential contributor to the development of Alzheimer's disease ([@bib76]), possibly as a result of abnormal phosphorylation of tau protein ([@bib106]). Insulin acting centrally also evokes efferent inputs into peripheral tissue metabolism ([@bib59]), contributing to the suppression of gluconeogenesis in the liver and the counterregulatory response to hypoglycemia ([@bib49]). Acting centrally on IR, insulin contributes to thermoregulation by activating heat-liberating mechanisms in brown adipose tissue ([@bib106]).

The cellular mechanisms underlying each of these complex, integrated responses are still to be elucidated, especially in so far as identification of the specific intra- and intercellular neuronal responses that are likely to be carefully decoded through spatial, temporal, and amplitude parameters. Although rich information is being gathered through electrophysiological approaches ([@bib202]; [@bib113]; [@bib114]), there is a rich opportunity to explore additional mechanisms through the advent of real-time intravital imaging of the central nervous system ([@bib62]).

Insulin in action: Stimulation of glucose uptake in muscle and fat cells {#s16}
========================================================================

The actions of insulin on the parenchyma of peripheral tissues are diverse, and paramount among them is the regulation of glucose metabolism. The major function of insulin in muscle and adipose tissues is to increase their uptake of carbon sources and store them for the energetic needs of tissue. With glucose transport into these tissues being rate limiting for its storage (as glycogen and triglycerides, respectively), it is no surprise that insulin regulates glucose uptake. This is brought about by an exquisite series of signals that cooperate in bringing glucose transporters (GLUT4 isoform) to the cell surface. This process is generically known as GLUT4 translocation, and 30 years of research has revealed regulation at a number of stages in this intracellular process ([@bib30]; [@bib100]; [@bib187]; [@bib19]; [@bib126]; [@bib108]; [@bib92]).

GLUT4 translocation takes places within minutes of insulin binding to its receptors at the surface of myocytes and adipocytes and does not involve internalization of the hormone. Major aspects of GLUT4 translocation are illustrated in [Fig. 5](#fig5){ref-type="fig"}.

![**Insulin signaling in muscle and adipose cells leading to recruitment of GLUT4 to the plasma membrane.** Insulin binds to its receptor on the surface of muscle or fat cells and activates the canonical insulin-signaling cascade to PI3K and Akt. Downstream of Akt, phosphorylation of AS160 allows for the full activation of Rab8A and Rab13 (in muscle cells) and Rab10 (in adipocytes). In the perinuclear region, Rab8A engages with its effector, MyoVa, and Rab10 with its effector, Sec16A, to promote outward vesicle traffic. Near the plasma membrane, Rab13 engages with MICAL-L2 and Actinin-4, whereas Rab10 engages with RalA, Myo1c, and Exocyst components. Simultaneously, downstream of PI3K, insulin leads to activation of Rac1 that promotes a dynamic cycle of cortical actin remodeling. Together, these actions tether GLUT4 vesicles to the actin cytoskeleton near the plasma membrane. Inset: Docked GLUT4 vesicle ready to fuse with the plasma membrane. Immobilized GLUT4 vesicles fuse with the membrane through formation of a SNARE complex between vesicular VAMP2 and syntaxin4 and SNAP23 on the plasma membrane.](JCB_201802095_Fig5){#fig5}

The unique GLUT4 compartment {#s17}
----------------------------

The molecular signature of GLUT4 allows it to be diverted away from the continuously recycling pathway (a ubiquitous intracellular route that constantly removes and returns membrane proteins by internalization toward endosomes and reexternalization) to constitute a functionally defined "organelle" called GLUT4 storage vesicles. Several elements contribute to the genesis and maintenance of this storage compartment, including sortilin ([@bib89]), the Rab GTPase-activating protein (GAP) AS160/TBC1D4, syntaxin 6/16 ([@bib30]; [@bib108]), the cleavable tether protein TUG ([@bib14]), and, in human muscle, clathrin heavy chain 22 ([@bib203]). The storage compartment is in dynamic communication with recycling endosomes ([@bib43]; [@bib103]; [@bib100]). This dynamic sorting generates a steady state whereby the majority (∼90--95%) of GLUT4 resides intracellularly at any point in time in both muscle and adipose cells. This effective removal from the plasma membrane at any point in time is rather unique for GLUT4, as is its intracellular sorting to a compartment that is only slowly or ineffectively available for recycling.

Insulin signals quickly mobilize GLUT4-containing vesicles of ∼70 nm in diameter from perinuclear/cytosolic depots toward the cell periphery. These emanate directly from the storage compartment; however, insulin also appears to redirect vesicles from this compartment toward the general recycling endosomes, from whence they reach the cell periphery in the form of somewhat larger vesicles ([@bib216]). A current model proposes that the initial gain in surface GLUT4 emanates from the storage compartment, whereas maintenance of the steady state involves the endosomal route ([@bib30]; [@bib100]; [@bib187]; [@bib19]; [@bib126]; [@bib108]; [@bib92]). However, another prevailing model proposes that the majority of vesicles furnishing the cell membrane with GLUT4 contain the fusogenic protein VAMP2, which segregates away with the storage compartment and is largely absent from recycling endosomes ([@bib159], [@bib160]; [@bib200]). Once at the cell periphery, insulin signals further promote vesicle fusion with the plasma membrane. Within minutes, this concerted action brings about a new steady state with double the number of GLUT4 units at the plasma membrane in muscle cells. Although this gain represents only ∼20% of the total GLUT4, given the large mass of muscle in vivo, this gain sustains the vastly preferential deposition of diet-ingested glucose into skeletal muscles. In adipocytes, the insulin-dependent gain in surface-exposed GLUT4 ranges from twofold (human) to 10-fold or higher (rodents) and is typically calculated that this gain involves 30--50% of the total GLUT4 complement in these cells. In both muscle and fat cells, the new steady state lasts for as long as insulin is present.

The GLUT4 polypeptide has a very long lifetime (∼40 h); hence, its continuous removal from the membrane allows for multiple rounds of endocytosis, sorting, and translocation. It is understood that insulin promotes GLUT4 exit from retention in the storage compartment ([@bib215]; [@bib43]; [@bib134]; [@bib20]) and also regulates GLUT4 vesicle tethering, docking, and fusion with the plasma membrane through mechanisms that borrow principles from those of synaptic vesicle and insulin granule fusion.

Insulin signals involved in GLUT4 translocation {#s18}
-----------------------------------------------

The connection between IR-derived signals ([@bib108]) and the elements that mobilize GLUT4 vesicles and enact their fusion with the membrane is beginning to unravel. Insulin activates the IR tyrosine kinase activity toward autophosphorylation by inducing structural rearrangement of the transmembrane domains to bring them into close proximity with each other ([@bib78]), and the consequent activation of the IR tyrosine kinase toward phosphorylation of its major substrates IRS1,2 ([@bib42]). Phosphorylation sites on IRS1,2 constitute entropic information to attract class I PI3K, which rapidly generates membrane domains enriched in PI(3,4,5)P~3~ (PIP~3~) within minutes ([@bib166]). Two major consequences of the PIP~3~ burst relevant for GLUT4 translocation are activation of the kinases Akt1, 2 ([@bib27]; [@bib210]) and of the Rho-family GTPase Rac1 ([@bib37]).

For the first signal, PIP~3~ attracts the PH domain of Akt, which makes the protein available for phosphorylation by two kinases, PDK-1, and mTORC2. Activated Akt1,2 migrates to the cytosol and intracellular membranes ([@bib222]), where it phosphorylates AS160, a substrate of 160 kD more appropriately named TBC1D4 ([@bib171]; [@bib119]). The TBC domain of AS160/TBC1D4 defines its GAP activity toward Rab family small GTPases. Phosphorylation of AS160/TBC1D4 inhibits its GAP activity; hence, insulin signaling leads to inactivation of an inhibitor of Rab GTPases. This realization constituted the first involvement of elements capable of specifically regulating vesicle traffic in the pathway, as Rab GTPases regulate vesicle fission, destination, and fusion. AS160/TBC1D4 targets a cluster of Rabs, particularly the phylogenetically related Rabs 8A, 10, and 13. In addition, these three GTPases are stabilized by the holdase chaperone RABIF/MSS4 ([@bib77]). As a result of AS160/TBC1D4 inactivation, these Rab GTPases prevail in their active, GTP-loaded state; hence, their regulation is largely via inhibition of their GAP (whereas their currently incompletely identified guanine nucleotide exchange factors (GEFs) might be constitutively active, as in the case of the Sec10, the GEF for Rab10 ([@bib174]; [Fig. 5](#fig5){ref-type="fig"}).

In parallel to activation of this "Akt cascade," the burst in plasma membrane--associated PIP~3~ leads to activation of GEFs (and possibly inhibition of GAPs) for Rac1 ([@bib192], [@bib193]). The resulting Rac1 activation leads to a dynamic remodeling of cortical actin filaments via cycles of actin filament branching enacted by Arp2/3 and actin severing enacted by cofilin, which is best mapped in muscle cells ([@bib36]) and tissue ([@bib191]; [Fig. 5](#fig5){ref-type="fig"}).

From signals to effectors: Mechanical elements of GLUT4 vesicle translocation {#s19}
-----------------------------------------------------------------------------

Rab GTPases lie at the crux of signal transmission to mechanical transduction, as several Rab GTPase effectors collude with actin filaments (whether those remodeling at the cell cortex and/or other filamentous configurations) to de facto mobilize GLUT4 to the plasma membrane. In adipocytes, Rab10 is the preferred GTPase in GLUT4 translocation ([@bib173]), whereas in muscle cells, it is Rab8A and Rab13 ([@bib91]; [@bib188], [@bib189], [@bib190]). Although Rab10, Rab8A, and Rab13 have been studied the most, other Rab family GTPases contribute to the overall GLUT4 traffic, such as Rab28, which is also a substrate of AS160/TBC1D4; Rab14, involved in intracellular GLUT4 sorting; Rabs 4 and 11, involved in constitutive GLUT4 cycling; and Rab5, involved in early GLUT4 endocytosis ([@bib92]).

In adipocytes, Rab10 promotes GLUT4 mobilization from the perinuclear region toward the plasma membrane ([@bib172]; [@bib29]), specifically by interacting with Sec16A ([@bib172]; [@bib29]). In addition, a function for Rab10 at the cell periphery was also proposed ([@bib35]), as will be discussed.

In muscle cells, the perinuclear Rab8A engages its effector Myosin Va thereby promoting GLUT4 exit from the storage compartment ([@bib189]). This processive molecular motor allows migration of GLUT4 vesicles along actin filaments toward the cell periphery. Rab13 is more peripherally located, and its effector is the cortically located protein MICAL-L2, which in turn binds the cortical cytoskeleton protein α-actinin4. In response to insulin, these three proteins can be visualized near the cell surface along with GLUT4 and cortical actin ([@bib190]). In this way, Rab8A and Rab13 ensure GLUT4 vesicle mobilization toward the periphery and tethering to cytoskeletal elements in this region, respectively.

In addition to the Rab13--MICAL-L2--α-actinin4 connection, GLUT4 vesicles tether to actin filaments via Myosin 1c ([@bib22]; [@bib21]). This restricts GLUT4 mobility beneath the membrane, a phenomenon nicely documented through total internal reflection fluorescence microscopy of muscle and adipose cells ([@bib9]; [@bib214]; [@bib21]; [@bib130]). GLUT4 vesicle retention near the membrane also involves the exocyst subunit Exo70 ([@bib130]). Tethering may be regulated by insulin, as stimulation leads to phosphorylation of Exo84 ([@bib201]). In addition, active Rab10 binds to Exoc6/6b ([@bib175]), and the Rab10 effector RalA and its GEF, Rlf, interact with exocyst components ([@bib102]).

The GLUT4 vesicle fusion machinery {#s20}
----------------------------------

GLUT4 vesicles immobilized at the cell periphery rapidly fuse with the membrane. This is brought about through formation of a SNARE complex between VAMP2 on the vesicles and synatxin4 and SNAP23 on the plasma membrane ([@bib34]; [@bib63]; [@bib199]). The formation of the SNARE complex is regulated by a fine balance of a number of proteins such as Munc18c, Synip, and Doc2b, which receive input emanating from Akt and the phosphatase PTP-1B ([@bib217]; [@bib65]; [@bib10]; [@bib71]; [Fig. 5](#fig5){ref-type="fig"}).

The kinetics, stoichiometry, and upstream regulation of the fusion step still need to be fully investigated. Intriguingly, there are studies of additional participation of Ca^2+^-regulated proteins such as Doc2b, Tctex1d2, and E-Syt1 ([@bib117]; [@bib64]; [@bib179]), and insulin-dependent Ca^2+^-spikes have been recorded in muscle cells ([@bib41]), suggesting that the ion may impart some fine-tuning to the fidelity and timeliness of GLUT4 vesicle fusion. Lastly, and importantly, the fusion event requires insulin-induced actin polymerization, evincing the contribution of the actin cytoskeleton at different steps in the process of GLUT4 translocation ([@bib131]).

The end: Insulin degradation in the kidney {#s21}
==========================================

Insulin is no longer detectable in the circulation 30 min after its release from the pancreas, and its half-life once in the circulation is ∼6 min ([@bib162]; [@bib133]). In addition to its clearance by the liver (50% in first and another 25% in second pass), the hormone is also slowly internalized by most cells, including myoblasts and adipocytes, where it is routed to the lysosome for degradation. This is a mechanism to end insulin action, but it accounts for the destruction of only a fraction of the circulating insulin. The brunt of the degradation of the circulating hormone remaining after second pass through the liver occurs when it reaches the kidney. Here, its fate is threesome. Upon filtration at the level of the glomeruli, insulin enters the luminal space and reaches the proximal tubule, from whence it is rapidly reabsorbed by the renal epithelial cells. This reabsorption involves saturable binding to low-affinity, high-capacity sites at the brush border membrane, which are demonstrated to be not the IR ([@bib138]; [@bib177]; [@bib147], [@bib148]) but possibly scavenger receptors such as megalin (member of the low-density lipoprotein receptor family; [@bib38]; [@bib111]) and cubilin, proteins that recover a number of proteins by endocytosis. Insulin thus internalized enters the retroendocytic pathway, where it dissociates from its binding sites to proceed to lysosomes for degradation.

Second, about an equal amount of insulin also enters renal tubular cells from the contraluminal side facing the renal peritubular capillaries, especially in the convoluted tubule ([@bib158]). Here, IRs on the epithelial cells bind insulin and transport it intracellularly for degradation ([@bib149]). In addition, these IR are important sites sensing the hormone to stimulate important functions such as reabsorption of sodium, phosphate, and glucose ([@bib158]; [@bib81]). It has been proposed that these two renal mechanisms of insulin internalization are responsible for clearing up to 6--8 U insulin per day ([@bib151]) amounting to up to 25% of the insulin secreted by the pancreas, or ∼50% of the circulating insulin, although this might be an overestimation. Nonetheless, renal insulin clearance may explain the curious fact that type 1 diabetic patients with onset renal failure can end up reducing their requirement for injected insulin ([@bib165]; [@bib158]).

Third, though most of the internalized insulin is degraded by the above pathways, a small fraction is reabsorbed back to the renal circulation through retroendocytosis ([@bib45]). Notably, alterations in insulin renal clearance prolong the permanence of insulin in the blood ([@bib45]), evincing the importance of this process to insulin's half-life in the circulation.

Concluding remarks {#s22}
==================

We have analyzed the fundamental physiological journey of insulin in the body by alternating a bird's-eye view of the integrative phenomenon with close-ups into the key cellular processes of the hormone's secretion, partial clearance in the liver, distribution to the circulation and exit to target tissues, its action to promote glucose uptake in muscle and fat, and ultimately its degradation in the kidney. In spite of the depth of knowledge available to us on each of these cellular stages in the journey, there are many mechanistic and integrated aspects that remain unknown. However, the current knowledge already allows us to understand how each stage is in communication with the other. The temporal periodicity of insulin secretion out of the pancreas is sensed by the hepatocytes, which synchronously clear a portion of the secreted insulin; insulin action on the macrovasculature allows recruitment of the microcirculation for full enactment of insulin delivery to tissues; and insulin action in the liver, muscle, and fat cells results in a lowering of blood glucose, thus terminating the prime stimulus for insulin secretion. In pace with insulin action, the kidney engages in its subsequent degradation, putting an end to the hormone's action with just the right time delay to ensure optimal metabolic homeostasis.
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